BioCentury | Jun 7, 2018
Preclinical News

Targeting tumor cilia could reverse resistance to kinase inhibitors

...saw more, longer cilia in three cell lines with acquired resistance to kinase inhibitors -- EML4-ALK oncogenic fusion protein (EML4-ALK)-positive...
BioCentury | Jul 27, 2017
Translation in Brief

Better glioma mouse models

...CRISPR-associated protein 9) with two guide RNAs (gRNA) to induce chromosomal rearrangements that yielded the EML4-ALK oncogenic fusion protein (EML4-ALK)...
...Communications (2017) Mark Zipkin, Staff Writer entrectinib Ignyta Inc. Memorial Sloan Kettering Cancer Center Nerviano Medical Sciences s.r.l. CRISPR-associated protein 9 (Cas9) EML4-ALK oncogenic fusion protein (EML4-ALK) Neurotrophic...
BioCentury | Oct 13, 2016
Strategy

Exosomes in the zone

...of Defense, Washington, D.C. Targets and Compounds EGFR - Epidermal growth factor receptor EML4-ALK - EML4-ALK oncogenic fusion protein...
BioCentury | Apr 7, 2016
Tools & Techniques

Sexy sequencing

Tim Harris, Venture Partner, SV Life Sciences The days when PhDs were minted based on sequencing a few nucleotides at the end of a piece of nucleic acid are definitely gone. The countless hours spent...
BioCentury | Feb 15, 2016
Emerging Company Profile

Platelet portrait

thromboDx B.V. has found a new repository to mine for disease diagnosis and treatment response: platelets. The company's most advanced programs are for cancer, where the technology could be easier to use and provide a...
BioCentury | Oct 5, 2015
Clinical News

EML4-ALK assay: Clinical trial data

An analysis of plasma samples from 24 patients with stage IV NSCLC with known anaplastic lymphoma kinase (ALK) tissue status determined by fluorescence in situ hybridization (FISH) showed that Exosome’s ExoDx Lung ALK assay had...
BioCentury | Sep 3, 2015
Distillery Therapeutics

Therapeutics: Anaplastic lymphoma kinase (ALK); EML4-ALK oncogenic fusion protein; MAP kinase kinase 1 (MAP2K1; MEK1); MAP2K2 (MEK2)

...lung cancers positive for the EML4-ALK oncogenic fusion protein . In human lung adenocarcinoma cell lines harboring the EML4-ALK oncogenic fusion protein...
...inhibitor of MAP2K1/MAP2K2, to treat advanced or metastatic melanoma. TARGET/MARKER/PATHWAY: Anaplastic lymphoma kinase (ALK) ; EML4-ALK oncogenic fusion protein...
BioCentury | Apr 27, 2015
Clinical News

EML4-ALK assay: Clinical trial data

An analysis of blood samples from 29 patients with NSCLC showed that Exosome’s EML4-ALK assay had 100% specificity for differentiating between the 3 major fusion transcript variants of EML4-ALK. No false positives were detected. Exosome...
BioCentury | Nov 13, 2014
Distillery Techniques

Technology: Disease models

...CRISPR-Cas9 genome editing could be useful for creating mice bearing oncogenic chromosomal arrangements such as EML4-ALK oncogenic fusion protein...
BioCentury | Oct 16, 2014
Distillery Techniques

Technology: Disease models

...The model was established via orthotopic implantation of NSCLC tumors from transgenic K-Ras (KRAS)- or EML4-ALK oncogenic fusion protein-mutant...
Items per page:
1 - 10 of 26